Posted by Michael Wonder on 06 Jul 2022
Regulatory submission for GSK's daprodustat accepted into Health Canada review
6 July 2022 - Canadian regulatory submission acceptance follows that of the US FDA and the EMA as well as the approval of Duvroq in Japan.
GSK announces that Health Canada has accepted into review the new drug submission for daprodustat, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor, for the potential treatment of patients with anaemia of chronic kidney disease.
